University of Zurich, Institute of Business Administration, UZH Business Working Paper No. 330
40 Pages Posted: 2 Oct 2010 Last revised: 22 Oct 2013
Date Written: October 22, 2013
Reference price systems for prescription drugs constitute widely adopted cost containment tools. In these systems, patients co-pay a fraction of the difference between a drug's pharmacy retail price and a reference price that is set by the government. Reference prices are either determined externally (based on drug prices in other countries) or internally (based on domestic drug prices). We study the effects of a change from external to internal reference pricing in Denmark in 2005. The reform led to substantial reductions in retail prices, reference prices and consumer co-payments as well as to sizable decreases in overall producer revenues and health care expenditures. The reform induced consumers to substitute away from branded drugs for which we estimate strong preferences. Therefore, as long as we include the perceived differences between branded and generic drugs in our consumer welfare estimation, the increase in consumer welfare due to the reform is relatively small.
Keywords: pharmaceutical markets, regulation, co-payments, reference pricing
JEL Classification: I18, C23
Suggested Citation: Suggested Citation
Kaiser, Ulrich and Mendez, Susan J. and Rønde, Thomas and Ullrich, Hannes, Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark (October 22, 2013). ZEW - Centre for European Economic Research Discussion Paper No. 10-062. Available at SSRN: https://ssrn.com/abstract=1685213 or http://dx.doi.org/10.2139/ssrn.1685213